Skip to main content
SpringerLink
Log in

Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG)

  • Research Paper
  • Published:
Science China Life Sciences Aims and scope Submit manuscript

Abstract

This study compared G-CSF/ATG and PTCy in myeloablative haploidentical hematopoietic stem cell transplantation (haplo-HSCT) for hematologic malignancies between January 2013 and March 2018 reporting to the Chinese Bone Marrow Transplantation Registry Group (CBMTRG). For each PTCy, G-CSF/ATG subjects (1:4) were selected using the nested case-pair method. In total, 220 patients including 176 in G-CSF/ATG group and 44 in PTCy group were analyzed. The incidences of 30-day neutrophil engraftment (88.6% vs. 96.6%, P=0.001), 90-day platelet engraftment (84.1% vs. 94.2%, P=0.04), the median time to neutrophil engraftment (17 days vs. 12 days, P=0.000) and platelet engraftment (22 days vs. 17 days, P=0.001) were significantly inferior in PTCy group. The incidences of grades 2–4 and 3–4 acute graft-versus-host disease (GVHD), chronic GVHD and severe chronic GVHD were comparable. Among G-CSF/ATG and PTCy groups, the 3-year progression-free survival, overall survival, cumulative incidences of nonrelapse mortality and relapse was 74.3% vs. 61% (P=0.045), 78.3% vs. 65.2% (P=0.039), 12% vs. 27.3% (P=0.008), and 14.9% vs. 11.7% (P=0.61), respectively. G-CSF/ATG can achieve better engraftment, PFS and OS, and lower incidence of NRM compared to PTCy in myeloablative haplo-HSCT for hematologic malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Apperley, J., Niederwieser, D., Huang, X., Nagler, A., Fuchs, E., Szer, J., and Kodera, Y. (2016). Reprint of: haploidentical hematopoietic stem cell transplantation: a global overview comparing asia, the european union, and the united states. Biol Blood Marrow Transplant 22, S15–S18.

    Article  Google Scholar 

  • Armand, P., Kim, H.T., Logan, B.R., Wang, Z., Alyea, E.P., Kalaycio, M.E., Maziarz, R.T., Antin, J.H., Soiffer, R.J., Weisdorf, D.J., et al. (2014). Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood 123, 3664–3671.

    Article  CAS  Google Scholar 

  • Bacigalupo, A., Dominietto, A., Ghiso, A., Di Grazia, C., Lamparelli, T., Gualandi, F., Bregante, S., Van Lint, M.T., Geroldi, S., Luchetti, S., et al. (2015). Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update. Bone Marrow Transplant 50, S37–S39.

    Article  CAS  Google Scholar 

  • Bashey, A., Zhang, X., Jackson, K., Brown, S., Ridgeway, M., Solh, M., Morris, L.E., Holland, H.K., and Solomon, S.R. (2016). Comparison of outcomes of hematopoietic cell transplants from T-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-identical sibling donors: a multivariable analysis including disease risk index. Biol Blood Marrow Transplant 22, 125–133.

    Article  CAS  Google Scholar 

  • Bashey, A., Zhang, X., Sizemore, C.A., Manion, K., Brown, S., Holland, H. K., Morris, L.E., and Solomon, S.R. (2013). T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 31, 1310–1316.

    Article  CAS  Google Scholar 

  • Blaise, D., Fürst, S., Crocchiolo, R., El-Cheikh, J., Granata, A., Harbi, S., Bouabdallah, R., Devillier, R., Bramanti, S., Lemarie, C., et al. (2016). Haploidentical T cell-replete transplantation with post-transplantation cyclophosphamide for patients in or above the sixth decade of age compared with allogeneic hematopoietic stem cell transplantation from an human leukocyte antigen-matched related or unrelated donor. Biol Blood Marrow Transplant 22, 119–124.

    Article  Google Scholar 

  • Chang, Y.J., and Huang, X.J. (2014). Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers. Bone Marrow Transplant 49, 873–879.

    Article  CAS  Google Scholar 

  • Cieri, N., Greco, R., Crucitti, L., Morelli, M., Giglio, F., Levati, G., Assanelli, A., Carrabba, M.G., Bellio, L., Milani, R., et al. (2015). Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative conditioning and peripheral blood stem cells. Biol Blood Marrow Transplant 21, 1506–1514.

    Article  CAS  Google Scholar 

  • Ciurea, S.O., Zhang, M.J., Bacigalupo, A.A., Bashey, A., Appelbaum, F.R., Aljitawi, O.S., Armand, P., Antin, J.H., Chen, J., Devine, S.M., et al. (2015). Haploidentical transplantwithposttransplantcyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood 126, 1033–1040.

    Article  CAS  Google Scholar 

  • Filipovich, A.H., Weisdorf, D., Pavletic, S., Socie, G., Wingard, J.R., Lee, S.J., Martin, P., Chien, J., Przepiorka, D., Couriel, D., et al. (2005). National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11, 945–956.

    Article  Google Scholar 

  • Finke, J., Bethge, W.A., Schmoor, C., Ottinger, H.D., Stelljes, M., Zander, A.R., Volin, L., Ruutu, T., Heim, D.A., Schwerdtfeger, R., et al. (2009). Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 10, 855–864.

    Article  CAS  Google Scholar 

  • Fuchs, E.J. (2015). HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide. Bone Marrow Transplant 50, S31–S36.

    Article  CAS  Google Scholar 

  • Handgretinger, R. (2014). Haploidentical transplantation: the search for the best donor. Blood 124, 827–828.

    Article  CAS  Google Scholar 

  • Jacoby, E., Chen, A., Loeb, D.M., Gamper, C.J., Zambidis, E., Llosa, N.J., Huo, J., Cooke, K.R., Jones, R., Fuchs, E., et al. (2016). Single-agent post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis after human leukocyte antigen-matched related bone marrow transplantation for pediatric and young adult patients with hematologic malignancies. Biol Blood Marrow Transplant 22, 112–118.

    Article  CAS  Google Scholar 

  • Kanakry, C.G., O’Donnell, P.V., Furlong, T., de Lima, M.J., Wei, W., Medeot, M., Mielcarek, M., Champlin, R.E., Jones, R.J., Thall, P.F., et al. (2014). Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol 32, 3497–3505.

    Article  CAS  Google Scholar 

  • Kasamon, Y.L., Bolaños-Meade, J., Prince, G.T., Tsai, H.L., McCurdy, S. R., Kanakry, J.A., Rosner, G.L., Brodsky, R.A., Perica, K., Smith, B.D., et al. (2015). Outcomes ofnonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol 33, 3152–3161.

    Article  CAS  Google Scholar 

  • Kröger, N., Solano, C., Wolschke, C., Bandini, G., Patriarca, F., Pini, M., Nagler, A., Selleri, C., Risitano, A., Messina, G., et al. (2016). Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med 374, 43–53.

    Article  Google Scholar 

  • Liu, Y., Huang, X., Fei, Q., Xu, L., Zhang, X., Liu, K., Chen, Y., Chen, H., and Wang, Y. (2019). Comparison analysis between haplo identical stem cell transplantation and matched sibling donor stem cell transplantation for high-risk acute myeloid leukemia in first complete remission. Sci China Life Sci 62, 691–697.

    Article  Google Scholar 

  • Luznik, L., Bolaños-Meade, J., Zahurak, M., Chen, A.R., Smith, B.D., Brodsky, R., Huff, C.A., Borrello, I., Matsui, W., Powell, J.D., et al. (2010). High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 115, 3224–3230.

    Article  CAS  Google Scholar 

  • McCurdy, S.R., Kanakry, J.A., Showel, M.M., Tsai, H.L., Bolaños-Meade, J., Rosner, G.L., Kanakry, C.G., Perica, K., Symons, H.J., Brodsky, R. A., et al. (2015). Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 125, 3024–3031.

    Article  CAS  Google Scholar 

  • McCurdy, S.R., Kasamon, Y.L., Kanakry, C.G., Bolaños-Meade, J., Tsai, H. L., Showel, M.M., Kanakry, J.A., Symons, H.J., Gojo, I., Smith, B.D., et al. (2017). Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica 102, 391–400.

    Article  CAS  Google Scholar 

  • Mehta, R.S., Saliba, R.M., Chen, J., Rondon, G., Hammerstrom, A.E., Alousi, A., Qazilbash, M., Bashir, Q., Ahmed, S., Popat, U., et al. (2016). Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol 173, 444–455.

    Article  CAS  Google Scholar 

  • Mielcarek, M., Furlong, T., O’Donnell, P.V., Storer, B.E., McCune, J.S., Storb, R., Carpenter, P.A., Flowers, M.E.D., Appelbaum, F.R., and Martin, P.J. (2016). Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood 127, 1502–1508.

    Article  CAS  Google Scholar 

  • Przepiorka D., Weisdorf, D., Martin, P., Klingemann, H.G., Beatty, P., Hows, J., Thomas, E.D., Przepiorka, D., Weisdorf, D., Martin, P., et al. (1995). 1994 consensus conference on acute gvhd grading. Bone Marrow Transplant 15, 825–828.

    CAS  PubMed  Google Scholar 

  • Robinson, T.M., O’Donnell, P.V., Fuchs, E.J., and Luznik, L. (2016). Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol 53, 90–97.

    Article  Google Scholar 

  • Rubio, M.T., Savani, B.N., Labopin, M., Piemontese, S., Polge, E., Ciceri, F., Bacigalupo, A., Arcese, W., Koc, Y., Beelen, D., et al. (2016). Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. J Hematol Oncol 9, 25.

    Article  Google Scholar 

  • Ruggeri, A., Sun, Y., Labopin, M., Bacigalupo, A., Lorentino, F., Arcese, W., Santarone, S., Gülbas, Z., Blaise, D., Messina, G., et al. (2017). Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft-versus-host disease prophylaxis in haploidentical transplant. Haematologica 102, 401–410.

    Article  Google Scholar 

  • Shabbir-Moosajee, M., Lombardi, L., and Ciurea, S.O. (2015). An overview of conditioning regimens for haploidentical stem cell transplantation with post-transplantation cyclophosphamide. Am J Hematol 90, 541–548.

    Article  CAS  Google Scholar 

  • Walker, I., Panzarella, T., Couban, S., Couture, F., Devins, G., Elemary, M., Gallagher, G., Kerr, H., Kuruvilla, J., Lee, S.J., et al. (2016). Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol 17, 164–173.

    Article  CAS  Google Scholar 

  • Wang, Y., Chang, Y.J., Chen, L., Xu, L.P., Bian, Z.L., Zhang, X.H., Yan, C. H., Liu, K.Y., and Huang, X.J. (2017). Low-dose post-transplant cyclophosphamide can mitigate gvhd and enhance the g-csf/atg induced gvhd protective activity and improve haploidentical transplant outcomes. Oncoimmunology 6, e1356152.

    Article  Google Scholar 

  • Wang, Y., Chen, H., Chen, J., Han, M., Hu, J.D., Jiong Hu, J.D., Huang, H., Lai, Y., Liu, D., Liu, Q., et al. (2018). The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. Cancer Lett 438, 63–75.

    Article  CAS  Google Scholar 

  • Wang, Y., Liu, Q.F., Xu, L.P., Liu, K.Y., Zhang, X.H., Ma, X., Wu, M.Q., Wu, D.P., and Huang, X.J. (2016). Haploidentical versus matched-sibling transplant in adults with philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase iii randomized study. Clin Cancer Res 22, 3467–3476.

    Article  CAS  Google Scholar 

  • Xu, L., Chen, H., Chen, J., Han, M., Huang, H., Lai, Y., Liu, D., Liu, Q., Liu, T., Jiang, M., et al. (2018). The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology. J Hematol Oncol 11, 33.

    Article  Google Scholar 

  • Yu, W., Wang, Y., Wu, D., Liu, Q., Xu, L., Zhang, X., Liu, K., and Huang, X. (2019). Comparison of efficacy between HLA6/6- and HLA3/6-matched haploidentical hematopoietic stem cell transplant in T-cell-replete transplants between parents and children. Sci China Life Sci 62, 104–111.

    Article  CAS  Google Scholar 

  • Yu, X., Xu, L., Chang, Y., Huang, X., and Zhao, X. (2018). Rapid reconstitution of NK1 cells after allogeneic transplantation is associated with a reduced incidence of graft-versus-host disease. Sci China Life Sci 61, 902–911.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81670167), the Foundation for Innovative Research Groups of the National Natural Science Foundation of China (81621001), and sponsored by the Fund for Fostering Young Scholars of Peking University Health Science Center (BMU2017PY010).

Author information

Author notes

  1. Contributed equally to this work

Authors and Affiliations

  1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China

    Feifei Tang, Lanping Xu, Xiaohui Zhang, Yu Wang & Xiaojun Huang

  2. Xiangya Hospital, Central South University, Changsha, 410008, China

    Yajing Xu

  3. PLA Army General Hospital, Beijing, 100700, China

    Huiren Chen

  4. Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China

    Qifa Liu

  5. The First Affiliated Hospital of Soochow University, Suzhou, 215006, China

    Depei Wu

  6. Peking-Tsinghua Center for Life Sciences, Beijing, 100871, China

    Xiaojun Huang

Authors
  1. Feifei Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yajing Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Huiren Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lanping Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiaohui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Qifa Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Depei Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xiaojun Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaojun Huang.

Additional information

Compliance and ethics

The author(s) declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, F., Xu, Y., Chen, H. et al. Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF/ATG and posttransplant cyclophosphamide: results from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG). Sci. China Life Sci. 63, 571–581 (2020). https://doi.org/10.1007/s11427-019-9594-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11427-019-9594-7

Keywords

Search

Navigation